Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma

Br J Haematol. 2022 Jul;198(2):e32-e34. doi: 10.1111/bjh.18228. Epub 2022 May 4.

Authors

Christopher Dittus¹, Jordan A Miller², Robert Wehbie³, Jorge J Castillo⁴

Affiliations

¹ Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
² University of North Carolina Medical Center, Chapel Hill, North Carolina, USA.
³ UNC REX Cancer Center of Wakefield, University of North Carolina at Chapel Hill, Raleigh, North Carolina, USA.
⁴ Hematologic Oncology Treatment Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

PMID: 35506301
DOI: 10.1111/bjh.18228

No abstract available

Keywords: chemotherapy; daratumumab; monoclonal antibodies; non-Hodgkin lymphoma; plasmablastic lymphoma.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carboplatin
Etoposide
Humans
Ifosfamide*
Neoplasm Recurrence, Local / drug therapy
Plasmablastic Lymphoma* / drug therapy
Salvage Therapy

Substances

Antibodies, Monoclonal
daratumumab
Etoposide
Carboplatin
Ifosfamide